Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06749847

HPV Self-sampling in the General Population

A randomized controlled trial comparing three strategies for cervical cancer screening: direct mailing of HPV self-sampling kit ("Outreach" arm), choice between self-sampling or healthcare provider sampling ("Choice" arm), and standard care (control arm) in two French departments.

Recruiting

Interested in participating?

Request Info

Key information

Age range

30 year–65 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Regional Cancer Screening Coordinating Centre, Aube site, Troyes, Aube, France

Loading trial locations.

About this study

In France, over 3,000 women are diagnosed annually with cervical cancer and 1,100 die from it, despite organized screening programs. The national screening coverage rate of 59% (2018- 2020) remains well below the European Union's recommended target of 70% and even further from the French Cancer Plan 2014-2019 objective of 80%. This study evaluates two innovative strategies to improve participation rates in two French departments (Marne and Aube). Eligible women aged 30-65 years will be randomized into three arms. The "Outreach" arm receives HPV self-sampling kit directly at home with SMS reminder at 3 months if no participation. The "Choice" arm can choose between ordering a self-sampling kit or visiting a healthcare provider with SMS reminder at 3 months if no participation. The control arm follows standard procedure with self-sampling offered at 12-month reminder. Women with positive HPV self-sampling tests will be followed for triage cytology, with assistance provided for appointments in the "Outreach" arm and reminders at 6 months post-positive result in the "Choice" arm. The study assesses participation rates, triage completion rates, feasibility, acceptability, and cost-effectiveness of these strategies. If successful, findings could inform modifications to the national organized screening program.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women aged 30 to 65 years old
  • Living in the study area (Departments of Marne and Aube, France)
  • At moderate risk of cervical cancer, i.e. eligible to the organised programme and receiving the first invitation of the screening round (not a reminder letter)

Exclusion criteria

  • Outside the target age (less than 30 years old, or 66 years old and more)
  • Already participating in the current screening round
  • Total hysterectomy
  • History of cervical cancer
  • Current follow-up for abnormal cervical screening result or cervical lesions

Treatment and study plan

Women receive invitation letter with HPV self-sampling kit

Other

Direct mailing of HPV self-sampling kit. Women receive HPV self-sampling kit with instructions. SMS reminder at 3 months if no participation. Assistance provided for triage cytology if HPV positive.

Women receive invitation letter with choice of ordering a free self-sampling kit or visit healthcare provider

Other

Option between self-sampling and healthcare provider: women can choose testing method. If self-sampling chosen, kit sent to home. SMS reminder at 3 months if no participation.

Primary outcomes

  1. Participation rate in cervical cancer screening

    Time frame: 18 months after invitation

Secondary outcomes

  1. Triage cytology completion rate after positive HPV test

    Time frame: 6 months after positive result

  2. HPV positivity rate

    Time frame: 12 months after invitation

  3. Invalid result rate

    Time frame: 18 months

  4. Time from HPV-positive result to completion of cytological triage

    Time frame: 18 months

  5. Women's acceptability of HPV self-sampling

    Time frame: 24 months

    Qualitative assessment through semi-structured interviews with 40 women to assess women's acceptability of HPV self-sampling

  6. Cost-effectiveness of screening strategies

    Time frame: 24 months

    Costs will be estimated using an ingredients approach whereby resources used for the respective interventions (' Outreach ' and ' Choice' strategies) are identified and valued. The analysis will include all costs incurred by the screening program, including invitation materials, self-sampling kits, laboratory testing, result communication, and follow-up coordination. The incremental cost-effectiveness ratios (ICERs) will be calculated as the mean difference in total costs between each intervention arm and the control arm, divided by the mean difference in screening participation rates. Results will be expressed in euros per percentage change in screening participation.

Study contacts

Contact information is provided by the study sponsor or research team.

Catherine Sauvaget, MD, PhD

CONTACT

[email protected]

+33 4 72738485

Farida Selmouni, PhD

CONTACT

[email protected]

+33 4 72738485

Sponsors and collaborators

Lead sponsor

International Agency for Research on Cancer

Other

Collaborators

  • CHU de Reims
  • Central Hospital, Nancy, France
  • National Cancer Institute, France

Registry information

Official study title

HPV Self-sampling in the General Population: Efficacy, Feasibility, Acceptability and Cost-effectiveness

Acronym: MIRABELLE

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 27, 2024
Registry last updated
Jul 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.